In a nutshell This study wanted to find out if people who have survived having melanoma cancer have higher levels of tiredness (fatigue) compared to those who have not had cancer. The study found that the people who survived having melanoma who were under 40 years old had slightly higher levels of fatigue compared to the general population. Some...
Read MoreMelanoma Posts on Medivizor
Evaluating pembrolizumab in patients with melanoma spread to the brain
In a nutshell This article investigated the safety and effectiveness of pembrolizumab (Keytruda) for patients with melanoma and untreated brain metastasis (the spread of cancer cells from the place where they first formed to another part of the body). The authors concluded that this therapy is safe and can improve the...
Read MoreAssociation of side effects and response to treatment in patients with melanoma treated with nivolumab
In a nutshell This study wanted to find out if patients with melanoma who had immune system side effects after treatment with nivolumab (Opdivo) had better outcomes than patients without side effects. The study found that the patients who had side effects from using nivolumab ended up with better responses to treatment and...
Read MoreAssociation of side effects and response to treatment in patients with melanoma treated with nivolumab
In a nutshell This study wanted to find out if patients with melanoma who had immune system side effects after treatment with nivolumab (Opdivo) had better outcomes than patients without side effects. The study found that the patients who had side effects from using nivolumab ended up with better responses to treatment and...
Read MorePV-10 for treating melanoma metastasis
In a nutshell This study wanted to find out if treating patients who had melanoma cancer that had spread with PV-10 resulted in better outcomes. The study found that treating melanoma tumors that had spread with PV-10 resulted in the tumors being destroyed, with very few side effects. Some background Melanoma cancer can commonly spread from the...
Read MoreImmune-checkpoint inhibitors and thyroid function in cancer patients
In a nutshell This study wanted to find out how many cancer patients who were receiving treatments which target the immune system end up with thyroid problems. The study found that there were higher numbers of these patients experiencing issues with the thyroid than previously reported. Some background There are a number of options for treatment of...
Read MorePaclitaxcel plus trametinib or pazopanib to treat advanced melanoma
In a nutshell This study wanted to find out which combination of medication is better for treatment of advanced melanoma, paclitaxel (Taxol), paclitaxel plus trametinib (Mekinist), or paclitaxel plus pazopanib (Votrient). The study found that paclitaxel and trametinib had the best response, but had a lot of side effects, and there was no effect on...
Read MoreFotemustine and temozolomide in treating advanced metastatic melanoma
In a nutshell This study wanted to find out how well two chemotherapy drugs, fotemustine (Muphoran) and temozolomide (Temodar) work in treating melanoma that had spread to other organs (metastatic melanoma). The study found that some of the patients responded to this combination of medications. Some background Metastatic melanoma can often be...
Read MoreCurrent guidelines for care and management of skin melanoma
In a nutshell This study wanted to give an outline on what the current guidelines are for treating skin melanoma. The study overall said that surgery is the best way to remove the melanoma. Removing wide area around the melanoma is a good idea to make sure all the cancer cells are removed. Some background Skin melanoma can sometimes be...
Read MoreDabrafenib and trametinib for treatment of melanoma after surgery
In a nutshell This study wanted to see how long patients with melanoma would take to relapse (stop responding) when treated with dabrafenib (Tafinlar) plus tramentinib (Mekinst) after surgery. The study found that after four-years, the relapse rate was 59% compared to 40% in those who did not use the medications after surgery. Some background A...
Read MoreRetreatment with a second BRAF inhibitor in patients with advanced melanoma
In a nutshell This study wanted to see if using a different BRAF inhibitor was effective in the treatment of patients with melanoma. The study found that retreating with a slightly different BRAF inhibitor worked well. Some background Around 50% of patients with melanoma that has spread have a mutation in one of their genes. This gene is...
Read MoreWhich treatment works best, nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone for advanced melanoma
In a nutshell This study wanted to find out which medications are better for treating advanced melanoma; nivolumab (Opdivo) plus ipilimumab (Yervoy), nivolumab alone, or ipilimumab alone. The study found that using the combination of nivolumab and ipilimumab was more effective than using nivolumab alone, with the least...
Read More
